Xvivo Perfusion AB (publ)
XVIPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14 | $10 | $6 | $8 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $14 | $9 | $6 | $8 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 35.1% | 13.5% | 9.3% | 15.2% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS Diluted | 5.44 | 3.07 | 0.62 | 0.28 |
| % Growth | 77.2% | 395.2% | 121.4% | – |
| Operating Cash Flow | $0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |